Journal of International Psychiatry

【Abstract】 Objective To study the effects of different doses of olanzapine combined with modified electroconvulsive therapy (MECT) on serum levels of brain-derived neurotrophic factor (BDNF) and central nervous system specific protein β (S100β) in schizophrenia.Methods Select 142 schizophrenic patients admitted to our hospital from November 2020 to December 2021, and divide them into maintenance group and reduction group by lottery, with 71 cases in each group. All patients were treated with MECT, and the two groups were treated with olanzapine on the basis of MECT. The scores of positive and negative symptom scale (PANSS), Montreal Cognitive Assessment (MoCA) and Treatment Emergent Symptom Scale (TESS) were recorded, and the levels of BDNF and S100β were compared between the two groups.Results After treatment, the PANSS score of the two groups decreased significantly, which was lower in the reduction group than in the maintenance group (P < 0.05). After treatment, the MoCA scores of the two groups increased, which was higher in the reduction group than in the maintenance group (P < 0.05). After treatment, the level of BDNF in both groups increased, and the level of S100β in the reduction group was higher than that in the maintenance group, while that in the reduction group was lower than that in the maintenance group (P < 0.05). TESS scores of the patients in the two groups decreased after treatment, and those in the reduction group were lower than those in the maintenance group (P < 0.05).Conclusion Based on MECT treatment, slowly reducing the dose of olanzapine can effectively improve the symptoms and cognitive function of patients, and can reduce the degree of brain injury and restore brain function, with good safety.

【Key words】Olanzapine;Modified Electroconvulsive Therapy;schizophrenia;brain-derived neurotrophic factor